Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Inclusion Criteria: 1. Patient age \> 18 and \<85 years of age 2. Patients with CKD or ESRD with eGFR \< 30 mls/min 3. If receiving hemodialysis, patients must be on treatment \> 3 months 4. Normal healthy controls must be without a known history of CKD and be willing to have formal PSG test and plasma melatonin measurements Exclusion Criteria: 1. Patients receiving outpatient hemodialysis for \< 3 months 2. Patients with estimated GFR by Cockcroft Gault \> 30 mls/min 3. Patients receiving beta blocker therapy within one month of randomization 4. Patients receiving Nifedipine therapy within one month randomization 5. Patients on peritoneal dialysis 6. Patient with chronic home oxygen supplementation 7. Patients receiving chronic home CPAP therapy 8. Patients actively receiving outpatient sleep medications 9. Patients with diabetic gastroparesis unresponsive to medication 10. Patients with known pregnancy or unwilling to use contraception during the course of the study 11. Patients with a functioning renal allograft 12. Patient currently receiving long-term immunosuppressive therapy. Patients receiving low dose prednisone (10mg or less per day) will not be excluded from this trial 13. Unable to give informed consent